Literature DB >> 15361392

Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

R Cervera1, R A Asherson, M L Acevedo, J A Gómez-Puerta, G Espinosa, G De La Red, V Gil, M Ramos-Casals, M García-Carrasco, M Ingelmo, J Font.   

Abstract

OBJECTIVE: To describe and analyse the clinical characteristics of 100 patients with antiphospholipid syndrome (APS) associated with infections.
METHODS: Patients were identified by a computer assisted search (Medline) of published reports to locate all cases of APS published in English, Spanish, and French from 1983 to 2003. The bilateral Fisher exact test was used for statistics.
RESULTS: 59 female and 41 male patients were identified (mean (SD) age, 32 (18) years (range 1 to 78)): 68 had primary APS, 27 had systemic lupus erythematosus, two had "lupus-like" syndrome, two had inflammatory bowel disease, and one had rheumatoid arthritis. APS presented as a catastrophic syndrome in 40% of cases. The main clinical manifestations of APS included: pulmonary involvement (39%), skin involvement (36%), and renal involvement (35%; nine with renal thrombotic microangiopathy, RTMA). The main associated infections and agents included skin infection (18%), HIV (17%), pneumonia (14%), hepatitis C (13%), and urinary tract infection (10%). Anticoagulation was used in 74%, steroids in 53%, intravenous immunoglobulins in 20%, cyclophosphamide in 12%, plasma exchange in 12%, and dialysis in 9.6%. Twenty three patients died following infections and thrombotic episodes (16 with catastrophic APS). Patients given steroids had a better prognosis (p = 0.024). The presence of RTMA and requirement for dialysis carried a worse prognosis (p = 0.001 and p = 0.035, respectively).
CONCLUSIONS: Various different infections can be associated with thrombotic events in patients with APS, including the potentially lethal subset termed catastrophic APS. Aggressive treatment with anticoagulation, steroids, and appropriate antibiotic cover is necessary to improve the prognosis.

Entities:  

Mesh:

Year:  2004        PMID: 15361392      PMCID: PMC1754783          DOI: 10.1136/ard.2003.014175

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  84 in total

1.  Transient anticardiolipin antibody syndrome in a patient with parvovirus B19 infection.

Authors:  T Reitblat; T Drogenikov; I Sigalov; S Oren; D London
Journal:  Am J Med       Date:  2000-10-15       Impact factor: 4.965

2.  'Catastrophic' antiphospholipid syndrome.

Authors:  P J Maddison; C Thorpe; J R Seale; W Ahmed; G S Whiteley
Journal:  Lupus       Date:  2000       Impact factor: 2.911

3.  The relationship of antiphospholipid antibodies to infections--do they bind to infecting agents or may they even be induced by them?

Authors:  Y Shoenfeld; M Blank; I Krause
Journal:  Clin Exp Rheumatol       Date:  2000 Jul-Aug       Impact factor: 4.473

4.  Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases.

Authors:  H Amital; Y Levy; C Davidson; I Lundberg; A Harju; Y Kosach; R A Asherson; Y Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2001-10       Impact factor: 5.532

5.  Hughes syndrome associated with varicella infection.

Authors:  I Uthman; A Taher; I Khalil
Journal:  Rheumatol Int       Date:  2001-05       Impact factor: 2.631

Review 6.  The antiphospholipid syndrome and infection.

Authors:  G N Dalekos; K Zachou; C Liaskos
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

7.  Antiphospholipid syndrome induced by HIV.

Authors:  A N Leder; B Flansbaum; G Zandman-Goddard; R Asherson; Y Shoenfeld
Journal:  Lupus       Date:  2001       Impact factor: 2.911

8.  Antiphospholipid antibodies in leprotic patients: a correlation with disease manifestations.

Authors:  A Elbeialy; K Strassburger-Lorna; T Atsumi; M L Bertolaccini; O Amengual; M Hanafi; M A Khamashta; G R Hughes
Journal:  Clin Exp Rheumatol       Date:  2000 Jul-Aug       Impact factor: 4.473

9.  Pulmonary embolism and transitory anti-beta2-GPI antibodies in an adult with chicken pox.

Authors:  V Viseux; L Darnige; E Carmi; G Chaby; J F Poulain; R Cevallos; C Lok; J P Denoeux
Journal:  Lupus       Date:  2000       Impact factor: 2.911

Review 10.  Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature.

Authors:  P Brown; L Crane
Journal:  Clin Infect Dis       Date:  2001-03-26       Impact factor: 9.079

View more
  42 in total

Review 1.  Infectious origin of the antiphospholipid syndrome.

Authors:  Y Shoenfeld; M Blank; R Cervera; J Font; E Raschi; P-L Meroni
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

Review 2.  From molecular mimicry to cross-reactivity or pathogen expansion? A hypothesis.

Authors:  Alexander P Rozin
Journal:  Clin Rheumatol       Date:  2006-06-29       Impact factor: 2.980

Review 3.  Infections and the antiphospholipid syndrome.

Authors:  Mario García-Carrasco; Claudio Galarza-Maldonado; Claudia Mendoza-Pinto; Ricardo O Escarcega; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Pulmonary hemorrhage complicating Goodpasture's disease in the course of pulmonary tuberculosis.

Authors:  Yao-Ko Wen; Kai-I Wen
Journal:  Int Urol Nephrol       Date:  2012-07-24       Impact factor: 2.370

5.  SLE presenting as demyelinative autoimmune visual loss.

Authors:  Ami Schattner; Shilo Voichanski; Livnat Uliel
Journal:  BMJ Case Rep       Date:  2018-03-05

6.  Acute phase phospholipids related to the cardiolipin of mitochondria in the sera of patients with chronic fatigue syndrome (CFS), chronic Ciguatera fish poisoning (CCFP), and other diseases attributed to chemicals, Gulf War, and marine toxins.

Authors:  Yoshitsugi Hokama; Cara Empey-Campora; Cynthia Hara; Nicole Higa; Nathaniel Siu; Rachael Lau; Tina Kuribayashi; Kenichi Yabusaki
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

7.  Antiphospholipid syndrome and acute HIV infection.

Authors:  Jaime Solis Diaz; Juan Gomez Octavio; Manuel L Fernandez-Guerrero
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

8.  Non-haemorrhagic, bilateral adrenal infarction in a patient with antiphospholipid syndrome along with lupus myocarditis.

Authors:  Nicholas Marinus Batt; Dean Malik; Miranda Harvie; Hemant Sheth
Journal:  BMJ Case Rep       Date:  2016-07-20

Review 9.  Malignancies and catastrophic anti-phospholipid syndrome.

Authors:  Wolfgang Miesbach
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 10.  Systematic review of case reports of antiphospholipid syndrome following infection.

Authors:  N Abdel-Wahab; M A Lopez-Olivo; G P Pinto-Patarroyo; M E Suarez-Almazor
Journal:  Lupus       Date:  2016-04-07       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.